4/1
08:00 am
engn
enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum
Medium
Report
enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum
3/11
10:27 am
engn
enGene Holdings Inc. (NASDAQ: ENGN) had its price target lowered by analysts at Morgan Stanley from $37.00 to $34.00. They now have an "overweight" rating on the stock.
Low
Report
enGene Holdings Inc. (NASDAQ: ENGN) had its price target lowered by analysts at Morgan Stanley from $37.00 to $34.00. They now have an "overweight" rating on the stock.
3/11
08:15 am
engn
enGene Holdings Inc. (NASDAQ: ENGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Low
Report
enGene Holdings Inc. (NASDAQ: ENGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
3/10
04:34 pm
engn
enGene Reports First Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
enGene Reports First Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
3/10
04:05 pm
engn
enGene Reports First Quarter 2025 Financial Results and Provides Business Update
Low
Report
enGene Reports First Quarter 2025 Financial Results and Provides Business Update
3/4
08:00 am
engn
enGene to Participate in the Leerink Partners Global Healthcare Conference
Medium
Report
enGene to Participate in the Leerink Partners Global Healthcare Conference
2/18
07:37 am
engn
enGene Holdings Inc. (NASDAQ: ENGN) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $26.00 price target on the stock.
Low
Report
enGene Holdings Inc. (NASDAQ: ENGN) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $26.00 price target on the stock.
2/14
08:16 am
engn
enGene Holdings Inc. (NASDAQ: ENGN) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating. They now have a $7.00 price target on the stock, down previously from $34.00.
Low
Report
enGene Holdings Inc. (NASDAQ: ENGN) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating. They now have a $7.00 price target on the stock, down previously from $34.00.
2/4
08:37 am
engn
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Low
Report
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/4
08:00 am
engn
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Low
Report
enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
1/31
04:05 pm
engn
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
1/30
08:27 am
engn
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) [Yahoo! Finance]
Medium
Report
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) [Yahoo! Finance]
1/30
08:00 am
engn
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)
Medium
Report
enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)